EGEli Gilboa

Eli Gilboa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eli Gilboa has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Vaccination Against Pathogens Targeting Cell-Derived Cryptic Antigens

    by Emily S Clark, Greta Garrido, Agata Levay, Brett Schrand, Eli Gilboa

    CD8+ T-cell responses are an important component of a protective immune response in many pathogenic infections, including HIV and Herpesviridae such as cytomegalovirus (CMV) and Epstein-Barr virus (EBV). Identification of pathogen-encoded protective antigens, antigenic heterogeneity, and progressive immune dysfunction are major barriers facing the development of effective CD8+ T-cell–targeted vaccines. Here we tested the hypothesis that pathogen-infected cells can be sensitized to vaccination against host-derived antigens presented by the infected cells with reduced expression of TAP (transporter associated with antigen processing). In this study, we show the following: first, natural or targeted downregulation of TAP in CMV- and EBV- or HIV-infected cells, respectively, leads to the presentation of a cell-encoded nonmutated cryptic epitope, initially described in tumor cells with reduced TAP expression; second, peripheral blood mononuclear cell–derived CD8+ T cells enriched for multiple TAP downregulation–induced epitopes recognize TAPlow CMV-, EBV-, and HIV-infected cells, leading to the depletion of TAPlow-infected cells and the expression of activation markers in the T cells. This study describes a prototype of a universal drug formulation to vaccinate against tumors and pathogen-infected cells, dispensing with the need to identify pathogen- or tumor-specific antigenic targets and obviating the limitations associated with antigenic heterogeneity and immune dysfunction characteristic of pathogens such as HIV.

  • Open Access

    KLF2 inhibition expands tumor-resident T cells and enhances tumor immunity

    by Eli Gilboa, Vineet Gupta, Darija Muharemagic, Sunwoo Ham, Erietta Stelekati, Emily Clark

    Tissue resident memory CD8+ T cells (Trm) constitute a distinct population of non-circulating memory T cells1-5 vastly exceeding the number of circulating T cells5, and play a pivotal role in protective immunity against pathogens6-8. How to promote the generation of vaccine specific Trm remains an important challenge. Whether Trm contribute also to immune control of tumors or just correlate with an unrelated process linked to clinical outcome has not been unequivocally established9,10, and phenotypic markers such as co-expression of CD69 and CD103 or CD49a integrins commonly used to monitor tumor infiltrating Trm do not unambiguously define this subset. Here we tested the hypothesis that transient downregulation of KLF2, the most conserved feature of Trm ontogeny4,11,12, will promote the differentiation of vaccine activated CD8+ T cells into Trm and enhance antitumor immunity. We show that 4-1BB antibody targeted delivery of a KLF2 siRNA to tumor bearing mice led to the downregulation of KLF2 in vaccine activated CD8+ T cells and the accumulation of phenotypically defined intratumoral CD69+CD103+ and CD69+CD49a+ CD8+ T cells which correlated with enhanced control of tumor growth. This study could serve as the foundation of a broadly applicable and clinically useful way to promote the generation of vaccine specific Trm and provides direct evidence that intratumoral CD8+CD69+CD103+ and CD8+CD69+CD49a+ cells are indeed Trm and that Trm contribute to tumor immunity.

  • Open Access

    Vaccination against neoantigens induced in cross-priming cDC1 in vivo

    by Emily S. Clark, Ana Paula Benaduce, Wasif N. Khan, Olivier Martinez, Eli Gilboa

    The conventional type 1 dendritic cells (cDC1) play a pivotal role in protective immunity against pathogens and cancer. However, their low frequency in the blood and tissues limits their use in immune therapy. We have recently described a method to vaccinate against neoantigens that are induced in tumor cells by targeted delivery of a TAP siRNA to dendritic cells using a TLR9 binding CpG oligonucleotide. Since TLR9 is also expressed in immune suppressive myeloid populations TLR9 targeting could reduce the effectiveness of this approach. Here, we describe a modular multivalent antibody platform to target the TAP siRNA to resident Clec9a expressing cDC1 and show that it leads to selective and sustained TAP downregulation in cDC1 and inhibits tumor growth in mice more effectively than CpG targeted siRNA. To induce DC maturation an agonistic CD40 antibody was administered to the siRNA treated mice. To obviate the need for a second drug formulation and reduce the risk of toxicity, we exploited the multivalent nature of this targeting platform to co-deliver the TAP siRNA and a DC maturation agent, a CpG containing oligonucleotide, to cDC1 in vivo and show that it was more effective than Clec9a targeting of TAP siRNA in combination with CD40 antibody. This study describes a way to manipulate the function of cDC1 cells in vivo using a broadly applicable antibody-based targeting platform to deliver multiple biological agents to specific cells in vivo to potentiate (immune) therapy and to probe the biology of specific cell types in their natural settings.


  • Open Access

    FIGURE 1 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer

    by Siddharth Mehra, Vanessa T. Garrido, Austin R. Dosch, Purushottam Lamichhane, Supriya Srinivasan, Samara P. Singh, Zhiqun Zhou, Iago De Castro Silva, Chandrashekar Joshi, Yuguang Ban, et al.

    Uro A treatment downregulates PI3K/AKT/mTOR pathway, reduces primary tumor burden, alters the stromal composition and immunomodulatory profile of the TME in a spontaneous murine model of PDAC. A, mRNA levels of AKT1 in normal pancreatic tissue (Normal; n = 171) and patients with primary PDAC (Tumor; n = 179) from GTEx and pancreatic adenocarcinoma (PAAD) TCGA database. B, Representative H&E-stained pancreas sections and IHC imaging analysis demonstrating pAKT and pP70S6K expression in the pancreatic tissue sections of non–tumor-bearing Ptf1aCre, and tumor-bearing KPC and PKT GEMMs of PDAC. Quantification of relative areas of positive staining in (within the tumor area) tissue sections from vehicle, and Uro A-treated tumors are indicated in adjacent plots. C, Schematic of vehicle or Uro A (20 mg/kg/day) treatment in PKT mice. Treatment was initiated at 4.5 weeks of age when mice reproducibly developed palpable tumors and was continued for 3 weeks before sacrifice. D, Pancreas weight analysis of Uro A or vehicle-treated PKT mice. E, Western blot analysis showing decreased pAKT and pP70S6K in PKT mice pancreata after Uro A treatment as compared with vehicle-treated PKT mice, n = 3 mice/group. F, Representative H&E-stained tumor sections, and IHC imaging analysis demonstrating reduction in pAKT and pP70S6K expression within the ductal compartment of pancreatic tissue sections following Uro A treatment in PKT GEMM, n = 3 mice/group. G, Collagen 1, trichrome blue staining, and their corresponding quantification analysis in pancreatic tumor tissues harvested from PKT mice treated with Uro A or vehicle, n = 5 mice/group. H, Cytokine array profiling of pancreatic tumor tissues harvested from PKT mice treated with Uro A or vehicle. Scale bar = 50 μm. Individual datapoints with mean ± SEM are shown and compared by two-tailed unpaired t test for two group comparison and one-way ANOVA for multiple comparisons; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, P > 0.05.

  • Open Access

    FIGURE 4 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer

    by Siddharth Mehra, Vanessa T. Garrido, Austin R. Dosch, Purushottam Lamichhane, Supriya Srinivasan, Samara P. Singh, Zhiqun Zhou, Iago De Castro Silva, Chandrashekar Joshi, Yuguang Ban, et al.

    PD-1/PD-L1 expression in the PDAC TME with Uro A treatment. A, Immunofluorescence-based histologic analysis depicting PD-L1–positive cells within pancreatic tumor sections harvested from vehicle or Uro A-treated PKT mice. Mean of positive cells per field of view within the tumor area for each mouse is shown in adjacent plot, n = 4 mice per group. B, Western blot analysis demonstrating PD-L1 protein expression in whole pancreatic tumor lysates from vehicle- or Uro A-treated PKT mice. C, Flow cytometric analysis of PD-L1 expression in the macrophage population with representative PD-L1 histogram overlay of vehicle- and Uro A-treated PKT mice (right). Flow cytometric analysis of PD-1 expression on CD4+ T cells (D) and CD8+ T cells (E) with representative PD-1 histogram overlay of vehicle- and Uro A-treated groups (right) of pancreatic tumors from PKT mice. Individual datapoints with mean ± SEM are shown and compared by two-tailed unpaired t test. *, P < 0.05; ***, P < 0.001; ns, P > 0.05; MFI, mean fluorescence intensity.

  • Open Access

    Figure S4 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer

    by Siddharth Mehra, Vanessa T. Garrido, Austin R. Dosch, Purushottam Lamichhane, Supriya Srinivasan, Samara P. Singh, Zhiqun Zhou, Iago De Castro Silva, Chandrashekar Joshi, Yuguang Ban, et al.

    Tumor weight, mouse weight and cytokine profiling of Uro A treatment in PKT mice.

  • Open Access

    Figure S5 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer

    by Siddharth Mehra, Vanessa T. Garrido, Austin R. Dosch, Purushottam Lamichhane, Supriya Srinivasan, Samara P. Singh, Zhiqun Zhou, Iago De Castro Silva, Chandrashekar Joshi, Yuguang Ban, et al.

    Cytokine profiling of PKT tumors and KPC cells treated with PI3Ki or Uro A.

  • Open Access

    Figure S1 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer

    by Siddharth Mehra, Vanessa T. Garrido, Austin R. Dosch, Purushottam Lamichhane, Supriya Srinivasan, Samara P. Singh, Zhiqun Zhou, Iago De Castro Silva, Chandrashekar Joshi, Yuguang Ban, et al.

    Raw uncropped images of Western blot membranes for Figs.1e and 3d.

  • Open Access

    FIGURE 4 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer

    by Siddharth Mehra, Vanessa T. Garrido, Austin R. Dosch, Purushottam Lamichhane, Supriya Srinivasan, Samara P. Singh, Zhiqun Zhou, Iago De Castro Silva, Chandrashekar Joshi, Yuguang Ban, et al.

    PD-1/PD-L1 expression in the PDAC TME with Uro A treatment. A, Immunofluorescence-based histologic analysis depicting PD-L1–positive cells within pancreatic tumor sections harvested from vehicle or Uro A-treated PKT mice. Mean of positive cells per field of view within the tumor area for each mouse is shown in adjacent plot, n = 4 mice per group. B, Western blot analysis demonstrating PD-L1 protein expression in whole pancreatic tumor lysates from vehicle- or Uro A-treated PKT mice. C, Flow cytometric analysis of PD-L1 expression in the macrophage population with representative PD-L1 histogram overlay of vehicle- and Uro A-treated PKT mice (right). Flow cytometric analysis of PD-1 expression on CD4+ T cells (D) and CD8+ T cells (E) with representative PD-1 histogram overlay of vehicle- and Uro A-treated groups (right) of pancreatic tumors from PKT mice. Individual datapoints with mean ± SEM are shown and compared by two-tailed unpaired t test. *, P < 0.05; ***, P < 0.001; ns, P > 0.05; MFI, mean fluorescence intensity.

  • Open Access

    FIGURE 5 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer

    by Siddharth Mehra, Vanessa T. Garrido, Austin R. Dosch, Purushottam Lamichhane, Supriya Srinivasan, Samara P. Singh, Zhiqun Zhou, Iago De Castro Silva, Chandrashekar Joshi, Yuguang Ban, et al.

    Addition of αPD-1 blockade to Uro A treatment further decreases PDAC tumor burden and improves overall survival in PKT mice. A, Schematic representation of PKT mice treated with vehicle, Uro A, or Uro A in combination with aPD-1. B, Kaplan–Meier plot and log-rank test analysis showing superior survival of PKT mice treated with Uro A in combination with aPD-1 when compared with all other groups. C, Representative H&E-stained tumor sections after 3 weeks of drug treatment depicting significant presence of normal pancreatic architecture (highlighted in green) in PKT mice treated with combination therapy of Uro A and αPD-1 as compared with other treatment cohorts (scale bar = 50 μm). D, Percentage of tumor area (brown bar) relative to the normal pancreas (green bar) quantified within the whole pancreas, by capturing multiple fields of view in lower magnification. E–J, Flow cytometric assessment of the tumor-infiltrating adaptive immune compartment in mice treated with vehicle, Uro A (same mice cohort used in previous figures) or Uro A+aPD-1 depicting frequency of CD4+ (E) and CD8+ (F) T cells naïve, central memory, and effector memory populations. PD-1 MFI expression in CD8+ T cells (G) and PD-1 MFI expression in CD4+ T cells (H). Flow cytometric analysis of tumor-infiltrating effector memory CD4+ T cells showing frequency of Tregs (I), and Th1 (J) cells in mice treated with vehicle, Uro A or Uro A+aPD-1. Individual datapoints with mean ± SEM are shown and compared by one-way ANOVA test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, P > 0.05.